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Abstract. To bypass resistance due to limited entry into the
cell derivatives of cytarabine (CP-4055, elacytarabine) and
gemcitabine (CP-4126) containing a fatty acid chain at the 5'
position of the nucleoside were developed. CP-4055 showed
an increased retention of the active metabolite, the triphos-
phate. This characteristic was supposed to favor combinations,
such as with the tubulin antagonist docetaxel, the platinum
oxaliplatin and the antifolate pemetrexed. The role of the cell
cycle effects of CP-4055 and CP-4126 on the efficacy of the
combination with docetaxel or pemetrexed was determined.
The combination of CP-4055 with oxaliplatin and docetaxel
was also evaluated in a mouse xenograft model. CP-4055
induced a G2/M and S phase accumulation and CP-4126 an
S phase accumulation. Both analogs induced a dose-dependent
cell kill (apoptosis and necrosis). None of the docetaxel
combinations induced a synergistic effect. The combina-
tion of docetaxel with CP-4055 or CP-4126 induced a G2/M
accumulation in the A549 (lung cancer) cell line, but a
G0/G1 accumulation in the WiDR (colon cancer) cell line.
Preincubation with docetaxel induced an increased cell kill in
both cell lines. The combination with oxaliplatin showed a
synergistic effect in both cell lines. Combinations with
pemetrexed were antagonistic in both cell lines. In the A549
cell line pemetrexed with CP-4055 led to an increase of the
G0/G1 phase and the S phase. In WiDR the combination of
pemetrexed with CP-4055 increased the G0/G1 phase and
increased the cell kill. Pemetrexed with CP-4126 induced an
increase in the G0/G1 phase and the S phase in the A549 cell
line. In the xenograft study, on a colon cancer and a lung
metastasis model, the combination of CP-4055 with docetaxel
showed the best results. Treatment with CP-4055 followed
by docetaxel after 4 h resulted in a reduction in metastasis in
a lung metastasis model, and a favorable toxicity profile was
observed. In conclusion, the combinations with oxaliplatin
showed a synergistic effect in the combination studies.
Although the combinations with docetaxel did not show an
enhanced effect in the in vitro studies, this combination
revealed an increased effect in the xenograft model.
Introduction
The deoxynucleoside analogs cytarabine (Ara-C) and gem-
citabine (dFdC) are drugs commonly used in the treatment of
a variety of cancers, although cytarabine is restricted for use
in hematological malignancies (1). The rate-limiting step in
the activation of both drugs to their active triphosphate forms
is the conversion to the intermediate monophosphate by
deoxycytidine kinase (dCK) (1,2). Both drugs can be inacti-
vated by deoxycytidine deaminase (dCDA). The second
intermediate of dFdC, dFdC diphosphate, is known to inhibit
ribonucleotide reductase, which is essential in providing
deoxyribonucleotides required for DNA repair (3). DNA
polymerisation is stopped after incorporation of dFdC
triphosphate into DNA and one additional nucleotide, this
masked chain termination prevents removal of gemcitabine
by exonucleases (4). Ara-C triphosphate incorporation into
DNA also causes chain termination, while the active metabolite
of Ara-C can inhibit DNA polymerase by competitive
inhibition (5). Due to their hydrophilic nature these drugs are
dependent on the equilibrative and concentrative nucleoside
transporters (hENT and hCNT) to cross the cell membrane
into the cell (6,7). In order to enhance the uptake of the drugs
into the cell by making the drugs less hydrophilic, derivatives
containing a fatty acid side chain have been developed. The
fatty acid was esterified to the 5' position on the sugar moiety.
The derivatives of gemcitabine (CP-4126) and cytarabine
(CP-4055, elacytarabine) each contain a fatty acid with a
chain length of eighteen carbon atoms and one trans-double
bond (elaidic acid) in position 9. CP-4055 has shown remark-
able antitumor activity in various solid cancer xenografts in
which the parent drug Ara-C has no activity (8). Other studies
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(9-11) have demonstrated that CP-4055 is still dependent on
activation by dCK, but that the drug has a longer cellular
retention and a different effect on DNA and RNA synthesis
compared to Ara-C. CP-4126 was also able to inhibit the
deamination of dFdC. CP-4126 is currently in phase I clinical
studies in solid tumor patients (intravenous and oral
administration). CP-4055 has shown acceptable tolerability
in phase I studies (12) and is currently being tested in phase
II studies on solid tumors and leukemia. CP-4055 has shown
additive to synergistic antiproliferative activity in combina-
tions with gemcitabine, irinotecan, topotecan, cloretazine and
idarubicine (13). Ara-C and dFdC are usually applied in
combinations, but the efficacy of these combinations is
sometimes limited by their hydrophilic nature or limited
accumulation of the triphosphate. Therefore we investigated
whether the lipophilic derivatives would be equally or even
more effective in combinations with oxaliplatin and docetaxel.
Oxaliplatin is a platinum analog that, like cisplatin, forms
intra- and interstrand DNA, DNA-protein and protein adducts.
Adducts formed by oxaliplatin in the DNA form primary
lesions that block DNA replication and transcription (14).
Oxaliplatin is used in the treatment of colorectal cancer (15).
Gemcitabine combined with cisplatin is one of the most active
combinations in NSCLC (16) for which very pronounced
synergism was found for in vitro and in vivo combinations
with gemcitabine-cisplatin (17,18) and gemcitabine-oxaliplatin
(19-22).
Docetaxel promotes the polymerization of tubulin. The
microtubules formed in the presence of docetaxel are very
stable; this stability causes disruption of microtubule dynamics.
As microtubule dynamics is essential for cell division and
interphase processes, disruption of microtubule dynamics
leads to cell death (23).
Pemetrexed is a multitargeted antifolate that works by
inhibiting several key enzymes involved in cellular met-
abolism (24). Docetaxel and pemetrexed are used in the
treatment of lung cancer (25,26). Additive to synergistic
effects were found for combinations of gemcitabine with
docetaxel (27) and pemetrexed (28).
Since gemcitabine and pemetrexed are standard therapy
for NSCLC and oxaliplatin for colon cancer, we investigated
whether the lipophilic derivatives would enhance the anti-
proliferative activity of these drugs.
Materials and methods
Drugs. Pemetrexed (PMX) was obtained from the pharmacy
department of the VU University Medical Center. Docetaxel
(Doc) and oxaliplatin (OHP) were obtained from Sanofi-
Aventis (Paris, France). CP-4055 and CP-4126 were obtained
from Clavis Pharma (Oslo, Norway).
Cell lines. To test the activity of the drugs in vitro, we
selected a non-small cell lung cancer cell line (A549) (29), a
colon cancer cell line (WiDR) (30) and a variant of the
WiDR cell line that has been cultured under low folate
conditions (WiDR-LF). Normal cell culture medium contains
supraphysiological folate levels, which reduce the effect of
antifolates. So WiDR-LF was used because the folate levels
in low folate conditions are more representative for folate
levels in human plasma and therefore these data could be
more predictive for the activity of antifolates than results
obtained from cell lines cultured in high folate medium (30).
The parent cell lines were cultured in DMEM medium with
glutamine (BioWhittaker, Verviers, Belgium), supplemented
with 10% fetal calf serum (Gibco, New York, NY, USA) and
20 mM HEPES buffer (BioWhittaker). The WiDR-LF cell
line was cultured with dialyzed serum and 2.5 nM leucovorin
(Sigma-Aldrich, St. Louis, MO, USA).
Chemosensitivity assay. As chemosensitivity assays we used
the sulforhodamine-B (SRB) assay and the (4,5-dimethyl-
thiazol-2,5-diphenyl) tetrazolium bromide (MTT) assay (31).
Since antifolates tend to increase the size of cells, thus
increasing the protein content, the MTT assay was used in
the experiments with PMX. For the other experiments the
SRB assay was used. Cells were transferred to 96-well
plates; on day one a serial dilution of one drug was added to
the cells. Different combinations were used in this study,
such as a fixed ratio of both drugs and a serial combination
of one drug combined with a constant concentration of the
second drug. When using a 4-h preincubation the drug in a
constant concentration was always added 4 h before adding
the combination of a serial dilution and a constant concen-
tration, so the serial dilution is incubated for 72 h and the
constant concentration was incubated for a total of 76 h.
When using a combination based on the IC50 ratio of the
drugs, both drugs were added in a serial dilution. The relative
amount of cells at drug addition was determined by fixating
control wells at day 0 (drug addition) and processed as
described below. The other (treated and control) cells were
fixed after the incubation period, washed and stained with
SRB. The stained proteins were measured at 492 nm with an
automated spectrophotometric microplate reader (Tecan,
Salzburg, Austria); the measured optical density correlates
with the amount of cells at the moment of fixation. When
using the MTT assay the cells were incubated for 3 h with
MTT, DMSO was added to dissolve the crystals and the
plates were measured at 492 nm.
The data were plotted in a graph to give a growth inhibition
curve. From this growth inhibition curve the IC50 value was
determined by interpolating at the 50% growth level.
Median-drug effect analysis. The median-drug effect analysis
method (32) has been widely used for evaluation of potential
synergism between different drugs (33,34). The Calcusyn
software (Calcusyn 1.1.1, Biosoft, Cambridge, UK) devel-
oped by Chou and Talalay was used for this evaluation. Doses
are calculated by the formula: D=Dm[Fa/(1-Fa)]1/m; where
Dm is the dose required for 50% growth inhibition, Fa is the
fraction affected and m is the slope. The combination index
(CI) was calculated using: CI=[(D)1/(Dx)1]+[(D)2/(Dx)2]+
[a(D)1(D)2/(Dx)1(Dx)2]; where a=1 for mutually non-
exclusive drugs, (D)1 and (D)2 are the doses of the separate
drugs and the combination, and (Dx)1 and (Dx)2 are the
doses resulting in a growth inhibition of x%.
A CI of <0.9 indicates synergism, of 0.9-1.1 additivity
and of >1.1 antagonism. Experimental conditions that result
in a Fa of <0.5 are of dubious importance. The aim is to obtain
a significant effect, which means at least >50%, but preferably
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complete, growth inhibition. Hence, in in vitro models, only
the interval between Fa 0.5 and 0.95 is likely to be of interest
(35). Per experiment a mean CI of the data points with a Fa
higher than 0.5 was calculated and used for overall evaluation.
Cell cycle distribution and cell kill. In 6-well plates 5x104
cells were seeded and grown for 24 h. After 24 h one drug
was added at the IC50 concentration and combined with the
IC25 concentration of the other drug, similar to the cyto-
toxicity assay. After 72 h incubation the cells were harvested
and analyzed by incubation with a propidium iodide solution
(PI); containing 50 μg/ml PI, 0.1% (Tri-) sodium citrate,
0.1% Triton X-100 and 0.1 mg/ml RNase A (Qiagen, Hilden,
Germany). The PI-stained cells were measured on a flow
cytometer (FACScan, BD Benelux, Erembodegem-Aalst,
Belgium) and the results were analyzed with the Cellquest
software. The accumulation in the G1, S and G2/M phase
was described as fraction of the total accumulation in these
phases of the cell cycle. Accumulation in the SubG1 and
tetraploidy/debris was described as fraction of the total
distribution. The sub G1 fraction was evaluated as the dead
cell population (both apoptotic and necrotic).
Platinum-DNA accumulation. The experimental procedure
was based on a method described by van Moorsel et al (36).
Briefly, cells were treated for 24 h with 200 μM OHP alone
or combined with the IC25 concentration of CP-4055 or CP-
4126, after incubation the cells were washed and harvested.
DNA was isolated using the QIAamp DNA minikit (Qiagen)
and treated with RNAse (Qiagen) to remove all residual
RNA. DNA content and quality was estimated with a nanodrop
(Nanodrop technologies, Wilmington, DE, USA). A total of
0.1 volume sodium chloride (1.65 M) was added to the
dissolved DNA. A calibration curve was made using different
concentrations of OHP (0-1.5 μM) in TE-buffer containing
0.165 M sodium chloride. Platinum content of samples and
standards was determined using Zeeman atomic absorption
spectrometry (AAS) (Varian SpectrAA-10 atomic absorption
spectrometer; Varian, Palo Alto, CA, USA).
Xenograft study. Combinations of CP-4055 together with
OHP and Doc were tested in mouse models (37). Housing
and all procedures involving animals were performed
according to protocols approved by the animal care and use
committee, in compliance with the German Animal Protection
Law. 5776 human colon carcinoma was used because earlier
it was characterized for its sensitivity to gemcitabine, CP-
4126 and CP-4055 (unpublished data). Tumor fragments
were transplanted to Ncr:nu/nu mice. The murine Lewis
Lung (LL) carcinoma is an established tumor in Crl:BDF1
female mice; this model was used because it will cause
lung metastases, and has been used earlier to investigate
synergism of gemcitabine with cisplatin and docetaxel
(38,39). Endpoints for all but the LL were toxic death, body
weight, tumor volume, white blood cell count (WBC) and
thrombocyte count. For the LL cell line the endpoints were
toxic death, body weight, lung weight, lung metastasis, WBC
and red blood cell count. Each experiment consisted of 6-8
groups with 8 mice per group. One group was treated with
the vehicle (PBS); the others with: 1) CP-4055 at maximum
tolerated dose (MTD), 2) CP-4055 at MTD combined with
drug 2 at MTD, 3) CP-4055 at MTD combined with drug 2 at
50% MTD, 4) CP-4055 at MTD combined with drug 2 at
25% MTD, 5) CP-4055 at 50% MTD combined with drug 2
at 50% MTD and 6) CP-4055 at 25% MTD combined with
drug 2 at 25% MTD.
Results
The IC50 values for the single drugs are given in Table I. These
data were used as a basis for the combination experiments.
In order to determine at which concentrations CP-4055
and CP-4126 induced significant cell cycle effects, we
determined the concentration dependency for these drugs.
CP-4055 induced a G2/M and S phase accumulation in the
A549 cell line; S phase accumulation at the lower concentra-
tions and G2/M accumulation at the higher concentrations in
the WiDR cell line (Fig. 1). At the highest concentration a
different effect was observed, this was possibly because a lot
of cells did not survive the 72-h exposure to these high
concentrations of drugs. In both cell lines CP-4055 induced
dose-dependent cell kill (Fig. 2b) and in the A549 cell line it
also induced tetraploidy (Fig. 2c). CP-4126 increased S phase
accumulation and dose-dependent cell kill in both cell lines
(Figs 1 and 2a).
Because a sequential effect of gemcitabine combined with
taxanes was observed previously (38,40); Doc was combined
with CP-4055 or CP-4126 in different schedules. A preincu-
bation of 4 h with CP-4055 or CP-4126 did not increase the
sensitivity to docetaxel (Table II), similar to previous data
found with paclitaxel with gemcitabine (38). No increased
effect was observed after preincubation with Doc prior to
CP-4055. In the combination with CP-4126 preincubation
with docetaxel increased the sensitivity from antagonistic to
additive.
Combinations with OHP both induced a synergistic effect
in both cell lines (Fig. 3). The combination with CP-4055
gave CI values of 0.8 and 0.7 in the WiDR and A549 cell line
respectively, while the combination with CP-4126 gave values
0.9 and 0.7.
All combinations with PMX were antagonistic in both
cell lines with all different combinations that were tested
(Table II). PMX in a serial dilution and CP-4055 or CP-4126
in a fixed concentration induced antagonism in both cell lines.
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Table I. Sensitivity of the cell lines to the single drugs used
in the combination experiments.
–––––––––––––––––––––––––––––––––––––––––––––––––
Drug WiDR WiDR-LF A549
––––––––––––––––––––––––––––––––––––––––––––––––– 
CP-4055 0.76±0.21 0.76±0.21 0.26±0.05
CP-4126 0.01±0.003 0.01±0.003 0.008±0.001
OHP 2.36±0.43 2.29±0.51
Doc 0.0014±0.0003 0.001±0.0002
PMX 0.06±0.006 0.02±0.005 0.23±0.06
––––––––––––––––––––––––––––––––––––––––––––––––– 
Values are IC50 (μM) means ± SEM of three separate experiments.
IC50 values were determined after 72-h exposure to the drugs.
–––––––––––––––––––––––––––––––––––––––––––––––––
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In the low folate cell line a slight improvement was observed
for the combination with CP-4126, while the opposite was
observed with the combination with CP-4055. Adding both
PMX and CP-4055 or CP-4126 in a fixed ratio did also not
increase the effect.
Since scheduling affected the interaction of CP-4055 and
CP-4126 with PMX and Doc, we investigated whether their
cell cycle effects would give insight into the mechanism. The
combinations with PMX did not show an increase in cell kill
or tetraploidy and the cell cycle data demonstrated that the
combination had an effect very similar to PMX alone (Fig. 4).
In the A549 cell line Doc combined with CP-4055 increased
the accumulation of cells in the G2/M phase by 7% (Fig. 4).
However, with a preincubation of CP-4055 the increase was
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Figure 1. Dose-dependency of CP-4126 or CP-4055 on the cell cycle in the (a) A549 and (b) WiDR cell lines. Cells were exposed for 72-h incubation to
increasing concentrations of drugs. Values represent percentiles of at least three separate experiments; SEM was <9.8% of the mean.
Figure 2. Dose-dependency of CP-4126 or CP-4055 on cell kill (Sub G1, which includes apoptosis and necrosis) of (a) CP-4126 or (b) CP-4055, and the
effect of (c) CP-4055 on the tetraploidy (no effect of CP-4126 on tetraploidy was observed). Cells were exposed for 72 h-incubation to increasing
concentrations of drugs. Values represent percentiles of at least three separate experiments; SEM was <6.9% of the mean.
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found to be 11%. In the WiDR cell line Doc together with
CP-4055 increased the G0/G1 phase accumulation by 11%
but by preincubation with Doc this was reduced to 5%. In the
A549 cell line Doc together with CP-4126 increased the
accumulation of cells in the G2/M phase by 4%. Surprisingly,
in both cell lines both combinations increased the sub G1
phase, which was higher after preincubation compared to
simultaneous exposure (Fig. 5). In the A549 cell line pre-
incubation with CP-4055 increased cell kill from 7%
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Table II. Mean combination indices of the different combination experiments with OHP, PMX and Doc.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Combination Serial dilution Fixed (IC25) WiDR A549 WiDR-LF
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
PMX+CP-4126 PMX, CP-4126a - 3.5±0.7 2.1±0.8
PMX+CP-4055 PMX, CP-4055a - 1.5±0.3 1.6±0.4
PMX+CP-4126 PMX CP-4126 1.6±0.4 1.7±0.6 1.2±0.6
PMX+CP-4055 PMX CP-4055 1.1±0.1 2.1±0.2 3.1±0.3
Doc+CP-4126 Doc CP-4126 1.6±0.1 1.3±0.4
Doc+CP-4055 Doc CP-4055 1.3±0.2 1.1±0.3
Doc+CP-4126 Doc CP-4126b 1.7±0.5 2.3±1.1
Doc+CP-4055 Doc CP-4055b 2.2±0.3 1.5±0.4
CP-4126+Doc CP-4126 Docb 1.0±0.2
CP-4055+Doc CP-4055 Docb 1.5±0.04
OHP+CP-4126 OHP CP-4126 0.9±0.2 0.7±0.2
OHP+CP-4055 OHP CP-4055 0.8±0.2 0.7±0.3
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aBoth drugs were added in a serial dilution, in a fixed 1:1 ratio (IC50:IC50). b4-h preincubation before adding the combination. Values
represent mean CI values ± SEM of at least three separate experiments.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Figure 3. Representative fractional effect-combination index (CI) graph of
the combination of (a) OHP combined with CP-4055 and (b) OHP combined
with CP-4126 in the A549 cell line. OHP was added in a serial dilution and
CP-4055 and CP-4126 at a fixed IC25 concentration; (a) 0.0035 and (b)
0.004 μM. A CI of <0.9 indicates synergism, of 0.9-1.1 additivity and of
>1.1 antagonism. The mean CIs of three separate experiments in A549 were:
0.7±0.2 for CP-4126 and 0.7±0.3 for CP-4055, and in the WiDR cell line:
0.9±0.2 and 0.8±0.2, respectively.
Figure 4. Cell cycle effect by the combination PMX or Doc with CP-4126
or CP-4055 on the (a) WiDR and (b) A549 cell lines after 72-h incubation.
PMX was added at IC50 concentration, (a) 0.2 and (b) 0.05 μM. Doc was
added at IC50 concentration, (a) 0.01 and (b) 0.008 μM, CP-4126 at IC25
concentration (0.004 μM) and CP-4055 at IC25 concentration, (a) 0.0035 and
(b) 0.15 μM. Values represent percentiles ± SEM of at least three separate
experiments.
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(simultaneous) to 12% (preincubation), whereas in the WiDR
cell line preincubation with CP-4055 doubled the amount of
cell kill. This was also observed with preincubation of CP-4126
in both cell lines. In A549 and WiDR both combinations
increased tetraploidy, while the increase was the highest after
preincubation with CP-4055.
For mechanistic studies on OHP we focused on the DNA
adduct formation. Compared to OHP alone (0.68 pmol/μg
DNA) platinum DNA adduct formation was only slightly
increased in the WiDR cell line with the combination of OHP
together with CP-4126 (0.95 pmol/μg DNA; not significant).
For the other combinations no increase in adduct formation
was observed.
Several combinations were also tested in in vivo model
systems, in which we first investigated which drug could be
given at its MTD in combination. The major toxicity observed
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Table III. Combinations of CP-4055 with OHP in the 5776 colon carcinoma.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Compound Treatment Dose Toxic deaths BWCb Optimum T/Cc WBCd Thrombo
(days) (mg/kg) (days) (%) (%) (106/ml) (106/ml)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
PBS 13-17 0/8 -2 6.3±1.4 1122±117
CP-4055 13-17 30 0/7 -3 45 (27) 4.7±1.6 1161±136
13-17 15 0/7 -5 63 (23) 4.6±2.2 1136±126
OHP 13-15 2.5 6/8 -19 ne 1.6±1.1e 812±240
(18-22)
13-15 1.25 0/7 -13 11 (27)e 4.6±2.3 957±231
CP-4055 13-17 30 0/8 -21 10 (34)e 2.1±0.7e 843±170
OHP 13-15 1.25
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aMice were injected IP with CP-4055 on days 13-17, and with OHP on days 13-15. OHP was administered 4 h after CP-4055. bBody weight
change; crelative tumor volume, treated to control; dwhite blood cell count; ne, not evaluable. eSignificant to PBS.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Figure 5. Effect on cell kill (Sub G1, which includes apoptosis and necrosis) and tetraploidy by the combinations of Doc with CP-4126 or CP-4055 on the (a)
A549 and (b) WiDR cell lines after 72-h incubation. Doc was added at IC50 concentration, (a) 0.01 and (b) 0.008 μM, CP-4126 at IC25 concentration (0.004 μM)
and CP-4055 at IC25 concentration, (a) 0.0035 and (b) 0.15 μM. Values represent percentiles ± SEM of at least three separate experiments. Observed effects
were not significant.
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in mice treated with OHP as a single drug was leucopenia,
while Doc induced erythropenia and CP-4055 induced leuco-
penia in the Crl:BDF1 mice. The combination of CP-4055
and OHP induced leucopenia in both the Ncr:nu/nu and the
Crl:BDF1 mice, but toxicity was not acceptable when
combined at the MTD of OHP. The MTD was reached in the
combinations of CP-4055 (30 mg/kg) with OHP (2.5 mg/kg)
and in the combination of CP-4055 (15 mg/kg) with OHP
(5 mg/kg). The combination of CP-4055 with Doc induced
leucopenia and erythropenia, the level of leucopenia appeared
to decrease when using different treatment schedules.
The combination of CP-4055 with OHP in the colon 5776
model showed a similar effect to OHP alone at its MTD
(Table III). The combination with OHP in Lewis Lung did
not show a reduction in the amount of metastasis and also no
improvement over single drug treatment (Table IV). In the
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Table IV. Combinations of CP-4055 with OHP in the LL lung carcinoma.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Compound Treatment Dose Toxic deaths BWCb Lung weight Lung WBCd RBCe
(days) (mg/kg) (days) (%) (g)±SD mets/mousec (106/ml) (109/ml)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
PBS 0/8 3 0.56±0.25 ++++ 14.7±2.8 10.3±0.6
CP-4055 3-7 30 0/8 3 0.51±0.15 ++++ 10.3±0.9 9.6±0.3
3-7 15 0/8 3 0.62±0.12 ++++ 10.6±1.8 9.6±0.4
OHP 3-7 2.5 0/8 1 0.59±0.15 ++++ 4.9±0.9 9.2±0.4
3-7 1.25 0/8 4 0.63±0.19 ++++ 10.9±2.5 9.6±0.6
CP-4055 3-7 30 0/8 4 0.48±0.17 ++++ 7.6±2.7g 9.0±0.4
OHP 3-7 1.25
CP-4055 3-7 15 1/8 -5 0.34±0.1f +++ 2.4±0.8g 9.8±0.3
OHP 3-7 5 (13)
CP-4055 3-7 15 0/8 1 0.49±0.1f ++++ 5.2±1.6g 9.6±0.1
OHP 3-7 2.5
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aMice were injected IP with CP-4055 on days 3-7, and also with OHP on days 3-7. OHP was administered 4 h after CP-4055. bBody weight
change; c++++ >20 nodes, +++ 10-20 nodes; dwhite blood cell count; ered blood cell count; fsignificant to CP-4055 (unpaired, two tailed
t-test); gsignificant to PBS.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table V. Combinations of CP-4055 with Doc in the LL lung carcinoma.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Compound Treatment Dose Toxic deaths BWCb Lung WBCd RBCe
(days) (mg/kg) (days) (%) mets/mousec (106/ml) (109/ml)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
PBS 3-7,10-14 0/8 5 +++(+) 15.1±2.4 10±0.4
CP-4055 3-7 25 0/8 4 ++++ 8±1.6 9.2±0.3f
10-14
Doc 3, 7, 11 15 0/8 5 ++(+) 12.2±3.4 8.9±0.3f
3, 7, 11 7.5 0/8 3 ++ 12.8±2.9 9.4±0.3f
CP-4055 3-7 25 0/8 -1 ++ 6.4±1.4f 8.8±0.4f
10-14
Doc 3, 7, 11 7.5
CP-4055 3-7 12.5 0/8 3 ++ 9.7±3.4f 9.2±0.6f
10-14
Doc 3, 7, 11 7.5
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aMice were injected IP with CP-4055 on days 3-7 and on days 10-14, and with Doc on days 3, 7 and 11. Doc was administered 4 h after
CP-4055. bBody weight change; c++++ >20 nodes, +++ 10-20 nodes, ++ 6-10 nodes; dwhite blood cell count; ered blood cell count.
Significant to *CP-4055, +Doc, fPBS (unpaired, two tailed t-test).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
285-294.qxd  13/11/2009  02:34 ÌÌ  Page 291
Lewis Lung model Doc and CP-4055 as single drugs did not
affect the number of metastasis (Table V and Fig. 6). The
combination of both drugs caused a reduction in the number
of lung metastases. Different treatment schedules showed
that there was a reduction in the number of lung metastasis.
The best result was obtained with the combination of CP-4055
first and Doc after 4 h (Table VI and Fig. 6).
Discussion
The lipophilic fatty acid analogs of cytarabine (CP-4055) and
gemcitabine (CP-4126) were evaluated for a potential syn-
ergism with several clinically active cytotoxic drugs. A
synergistic effect with OHP and an additive effect with Doc
were observed in vitro. Evidence suggests that different cell
cycle effects formed the basis for these drug interactions. At
least additive effects for combinations with CP-4055 were
observed in vivo.
Both CP-4055 and CP-4126 showed a concentration-
dependent disruption of the cell cycle. CP-4055 induced
G2/M and S phase accumulation, and subsequent cell kill.
CP-4126 demonstrated an S phase accumulation similar to
the cell cycle effect observed with gemcitabine (41); it also
induced a major amount of cell kill. As deoxynucleoside
analogs act by incorporation into DNA they generally affect
the S phase of the cell cycle (42). The G2/M accumulation
induced by CP-4055 was observed with the higher con-
centrations (>IC50); at this high concentration part of the
damaged cells might progress to the next phase without the
damage being properly repaired. The downstream G2/M
checkpoint will in turn cause the cells to be arrested. In the
A549 cell line there was also a large amount of tetraploidy
possibly associated with the highest amount of disruption of
the cell cycle. It has been shown that after treatment with
DNA-damaging agents the HCT116 human colon carcinoma
cell line failed in chromosomal segregation after entry into
mitosis (43).
The combination of OHP with CP-4126 showed a syner-
gistic effect in both cell lines. OHP is part of the standard
treatment of colon cancer and cisplatin of NSCLC; there is
some evidence of clinical activity of the combination of OHP
and gemcitabine in NSCLC (19-22). This indicates that the
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Table VI. Combinations of CP-4055 with Doc in the LL lung carcinoma.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Compound Treatment Doseb Toxic deaths BWCc Lung WBCe RBCf
(days) (mg/kg) (days) (%) mets/moused (106/ml) (109/ml)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
PBS 3-7, 10-14 0/8 4 ++++ 14.6±2.9 10.6±0.3
CP-4055 3-7 30 0/8 3 ++++ 14.1±2.5 9.6±0.3g
10-14
Docetaxel 3, 7, 11 20 0/8 5 +++ 10.2±2.9 9.7±0.6g
CP-4055 3-7 25 (am) 0/8 -5 ++g 9.2±2.1g 9.0±0.4g
10-14
Docetaxel 3, 7, 11 15 (am)
CP-4055 3-7 25 (am) 0/8 -3 ++g,h 10.2±1.1g 8.9±0.3g
10-14
Docetaxel 3, 7, 11 15 (pm)
Docetaxel 3, 7, 11 15 (am) 0/8 3 +++g 10±1.7g 9.5±0.5g
CP-4055 3-7 25 (pm)
10-14
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aMice were injected IP with CP-4055 on days 3-7 and on days 10-14, and with Doc on days 3, 7 and 11. bam: injection in the morning, pm:
injection in the afternoon; cbody weight change; d++++ >20 nodes, +++ 10-20 nodes, ++ 6-10 nodes; ewhite blood cell count; fred blood cell
count. Significant to gPBS, hCP-4055. 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Figure 6. Lung weight in LL carcinoma lung metastasis model after treatment
with the single drugs and the combinations. Values represent means ±
standard deviation of 8 mice. The values of control mice are set at 100% and
those of treated mice are relative to this. See Tables V and VI for dose and
schedule. Significantly different compared to: +CP-4055, *docetaxel
(unpaired, two tailed t-test, p<0.05).
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combination of CP-4126 with OHP might be eligible for
further clinical development. The combination of OHP with
CP-4055 also showed a synergistic effect in both cell lines.
Because Ara-C is not active in solid tumors there is no
evidence of clinical activity of the combination with OHP.
However, since CP-4055 is active in solid tumor xenografts
in which Ara-C is inactive (8), CP-4055 should be
considered as a new drug in clinical development.
Accumulation and retention of Ara-CTP, the active
metabolite, showed a favorable profile compared to Ara-C
alone (Adema, et al, Proc Am Assoc Cancer Res 99th
Annual Metting, vol. 49: abs. 5740, 2008).
The analogs did not increase the amount of platinum
DNA adduct formation; this is possibly due to very low
concentrations of the analogs compared to the OHP concen-
tration. Similarly the doses of both OHP and CP-4055 had to
be decreased in the combination in vivo because of additive
toxicity, resulting in a similar antitumor effect as OHP alone.
Combinations with Doc showed that preincubation with
the derivatives did not improve the antiproliferative effect.
However the cell kill data (apoptosis and necrosis) indicate
that preincubation increased the amount of cell kill to levels
higher than the levels caused by Doc alone. This sequential
effect of gemcitabine combined with taxanes was observed
previously (38,40); where taxane preincubation also increased
the amount of cell kill. A sequential effect was also observed
in the xenograft study, where the preincubation with CP-4055
showed the highest pharmacological activity both concerning
antitumor effect and toxicity. Taking this evidence together it
seems that to achieve the best growth inhibition cells need to
accumulate DNA damage induced by CP-4055 before Doc
blocks the cell division. This shows that the schedule at
which the combination will be given in vivo is important for
the outcome.
In the combinations with PMX the best combination was
the one in which both separate drugs had an effect on the
same part of the cell cycle. It has been shown that in order to
achieve a synergistic effect in the combination of gemcita-
bine and PMX the sequence of incubation is very important
(44). In the latter study it was shown that PMX upregulated
the expression of dCK and the equilibrative nucleoside
transporter, which are important in the action of nucleoside
analogs, the transporter possibly more than dCK. Preincu-
bation with PMX would thus make the cells more sensitive to
the prodrugs by increasing uptake, but since the prodrugs are
independent of nucleoside transporters this mechanism is
redundant in this case, explaining the lack of synergy.
In conclusion, the combinations with oxaliplatin were
synergistic in the combination studies. Although the combina-
tions with docetaxel did not show an enhanced effect in the
combination studies based on antiproliferative assays, pre-
incubation did increase the amount of cell kill as measured
by apoptosis. The positive effect of preincubation with CP-
4055 shown in vitro was confirmed in the animal tumor
models in vivo.
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